Leishmaniasis Translation

 

  • Target disease: VL
  • Partners (since project start): TB Alliance, USA; Advinus Therapeutics, India; Endolytics, USA; Accelera, Italy; Aptuit, Italy; London School of Hygiene & Tropical Medicine (LSHTM), UK; Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Belgium
  • Project start: July 2010
  • Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland.
  • Project status: Completed

 

Overall Objective:

  • Fully investigate the profile of VL-2098 as an NCE for VL

 

From the initially selected 70 nitroimidazoles belonging to four chemical sub-classes, VL-2098 was identified as a very potent and safe molecule and was selected for in-depth evaluation of its efficacy, pharmacokinetic, and early safety profile on the basis of these preliminary results. This compound is potent against L. donovani in vitro and shows efficacy in acute and chronic VL animal models after oral dosing. Toxicology and pharmacokinetic studies were completed in 2014 and a batch of high purity active pharmaceutical ingredient (API) successfully manufactured.

Results performed in three animal species indicated a link between dose, length of treatment, and testicular toxicity. Further studies of longer duration were undertaken in the animal model most sensitive to the therapeutic window in order to determine the safety margin, as a result of which the decision was taken not to move the candidate forward.

Last update: October 2015